You are here: Industry Insights > MMV

News List

Zydus receives Orphan Drug Designation from US FDA for malaria treatment expresspharma
December 17, 2021
The Orphan Drug Designation provides up to seven years of marketing exclusivity in the US.
Zydus announces completion of Phase-I trials of ZY19489 expresspharma
February 05, 2021
Zydus Cadila announced that its anti-malarial compound ZY19489 (MMV253) in development with Swiss-based product development partnership Medicines for Malaria Venture (MMV) has now completed Phase I clinical evaluation [Reg’n Number ACTRN12619000127101].
GSK, MMV filing for Kozenis in paediatric populations with P. vivax malaria accepted by Australian TGA pharmaceutical-business-review
January 14, 2021
GSK and Medicines for Malaria Venture (MMV) announced today that the Australian Therapeutic Goods Administration (TGA) accepted the submission of a Category 1 application to extend the indication of single-dose Kozenis (tafenoquine) to paediatric ...
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa worldpharmanews
March 05, 2020
The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV).
EDCTP commits €21.9m to MMV-led malaria research consortium pharmaceutical-technology
March 04, 2020
The European and Developing Countries Clinical Trials Partnership (EDCTP) has granted €21.9m to the PAMAfrica research consortium.
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria biospectrumasia
April 23, 2019
The goal of VivAccess is to support introduction and increased access to the suite of radical cure products to address these challenges